PHARMACEUTICAL PRESS REVIEW from 5 to 8 March of AboutPharma
Transgene: results down in 2006
(Les Echos online – March 8, 2007)
Transgene, a French company specializing in biotechnology, announced that it recorded a net loss of 22 million euros in 2006. The company has declared that 2007 will be a key year, above all for the results of the trials on 3 products.
http://www.aboutpharma.it/notizia.asp?id=12891
(Les Echos online – March 8, 2007)
Transgene, a French company specializing in biotechnology, announced that it recorded a net loss of 22 million euros in 2006. The company has declared that 2007 will be a key year, above all for the results of the trials on 3 products.
http://www.aboutpharma.it/notizia.asp?id=12891
Relaunch of the pharmaceutical sector: Comparison of Companies-State-Regions
(Il Sole 24 Ore: page 21 – 8 March 2007)
The State-Regions confrontation has begun for the relaunch of the pharmaceutical sector. The companies presented a platform from which to start defining a 'new drug policy': one of the ways forward for innovation is the tax exemption of the 50% of the increase in spending on R&D investments over the previous year. For Farmindustria, the increase in the diffusion of off-patent drugs is also fine, but without creating a 'protected' generic market. Assogenerici, on the other hand, is asking for less bureaucracy to obtain marketing authorizations and the cancellation of Italian-style patent protection. On over-the-counter medicines, ANIFA would like an increase in the offer with the transition from prescription to self-medication and with the use of brands.
http://www.aboutpharma.it/notizia.asp?id=12890
(Il Sole 24 Ore: page 21 – 8 March 2007)
The State-Regions confrontation has begun for the relaunch of the pharmaceutical sector. The companies presented a platform from which to start defining a 'new drug policy': one of the ways forward for innovation is the tax exemption of the 50% of the increase in spending on R&D investments over the previous year. For Farmindustria, the increase in the diffusion of off-patent drugs is also fine, but without creating a 'protected' generic market. Assogenerici, on the other hand, is asking for less bureaucracy to obtain marketing authorizations and the cancellation of Italian-style patent protection. On over-the-counter medicines, ANIFA would like an increase in the offer with the transition from prescription to self-medication and with the use of brands.
http://www.aboutpharma.it/notizia.asp?id=12890
Boiron: growing turnover of 5%
(Les Echos online – March 8, 2007)
Boiron, a French company specializing in homeopathy, in these first months of 2007 achieved a turnover that increased by 5% compared to the loss of 0.4% achieved in the same period of 2006. In 2006 the acquisition of Dolisos, which took place in 2004 , still had repercussions on costs, which amounted to 8.5 million euros. In Russia, the subsidiary created in 2005 has given a lot of satisfaction: 4 million euros of packages marketed.
http://www.aboutpharma.it/notizia.asp?id=12889
(Les Echos online – March 8, 2007)
Boiron, a French company specializing in homeopathy, in these first months of 2007 achieved a turnover that increased by 5% compared to the loss of 0.4% achieved in the same period of 2006. In 2006 the acquisition of Dolisos, which took place in 2004 , still had repercussions on costs, which amounted to 8.5 million euros. In Russia, the subsidiary created in 2005 has given a lot of satisfaction: 4 million euros of packages marketed.
http://www.aboutpharma.it/notizia.asp?id=12889
Acambis: change of CEO and restructuring plan
(The Financial Times online - March 8, 2007)
Acambis has decided to change the top management of the company. Gordon Cameron, who has been in office for 3 years as CEO, will be replaced by Ian Garland, who comes from Arrow Therapeutics, a biotech group bought by AstraZeneca last June. The decision was taken as part of a restructuring plan which aims to reduce costs by one fifth.
http://www.aboutpharma.it/notizia.asp?id=12888
(The Financial Times online - March 8, 2007)
Acambis has decided to change the top management of the company. Gordon Cameron, who has been in office for 3 years as CEO, will be replaced by Ian Garland, who comes from Arrow Therapeutics, a biotech group bought by AstraZeneca last June. The decision was taken as part of a restructuring plan which aims to reduce costs by one fifth.
http://www.aboutpharma.it/notizia.asp?id=12888
"False 'miracle' drugs. They will go to trial in four"
(la Repubblica Milan page II – 8 March 2007)
Prosecutor Francesco Prete has asked for the indictment of 4 people: the inventor of Biotex, his wife and 2 doctors. They had invented this product calling it 'miraculous' for the cure of all diseases, in reality it was a dietary supplement. The charge is of conspiracy, fraud and abusive exercise of the profession.
http://www.aboutpharma.it/notizia.asp?id=12887
(la Repubblica Milan page II – 8 March 2007)
Prosecutor Francesco Prete has asked for the indictment of 4 people: the inventor of Biotex, his wife and 2 doctors. They had invented this product calling it 'miraculous' for the cure of all diseases, in reality it was a dietary supplement. The charge is of conspiracy, fraud and abusive exercise of the profession.
http://www.aboutpharma.it/notizia.asp?id=12887
"Cosmo Pharma cuts IPO fork"
(Bloomberg Finance & Mer
(Bloomberg Finance & Mer
